Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 42.23 as of 2026-10-06T14:32:33.294Z.
Consensus retrieved: 2026-10-06T13:16:22.041Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:32:33.294Z.
Quote observation: 2026-10-06T14:30:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea97e6614670234c5dbfdf3bc7583d3b35e8d285e8978cbe73844bd7e5ba46ca
Forward PE Ratio (42.23) = Dated Quote Price ($321.24) / Consensus Forward EPS ($7.61)
FORWARD PE RATIO
42.23
SECTOR MEDIAN · HEALTHCARE
19.32
median of 154 covered companies
CURRENT VS SECTOR MEDIAN
+118.53%
vs the sector median at left
Krystal Biotech, Inc.
Market Cap
$9.47B
Forward PE Ratio
42.23
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $9.47B | 42.23 |
| Insulet Corp. (PODD)vs › | $9.32B | 20.70 |
| Henry Schein, Inc. (HSIC)vs › | $9.72B | 15.84 |
| Bruker Corporation (BRKR)vs › | $9.10B | 28.18 |
| The Ensign Group, Inc. (ENSG)vs › | $10.00B | 22.01 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.06B | 38.33 |
| Molina Healthcare, Inc. (MOH)vs › | $10.06B | N/A |
| Bruker Corporation (BRKRP)vs › | $8.83B | 207.35 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.78B | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.23B | 12.65 |
Trailing P/E
40.3
reported TTM EPS
Forward P/E
42.2
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $7.61 implies -4.6% EPS decline vs the reported trailing $7.98.
At the dated quote price of $321.24, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $7.61 | $7.10 – $8.19 | 9 | 42.2x |
| 2027-12-31 | $9.35 | $6.94 – $12.29 | 9 | 34.3x |
| 2028-12-31 | $14.70 | $6.97 – $21.08 | 7 | 21.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
